Open an account

Ocugen

OCGN · NASDAQ

$0.8125+$0.0252 (+3.20%)TodayMarket closed ·
Prev close $0.7873

About OCGN

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 116 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

Employees
116
Headquarters
Malvern, Pennsylvania
Listed
Dec 3, 2014
Sector
Health Care
Industry
Biotechnology
Website
ocugen.com

OCGN key statistics

Market cap
275.53M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.81M
Volume
6.66M
Open price
$0.79
High today
$0.84
Low today
$0.786
52 Week high
$2.73
52 Week low
$0.7803

Ocugen (OCGN) at a glance

Ocugen (OCGN) last traded at $0.8125, with a market cap of 275.53M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.786 and $0.84. The current price is 3.4% above the day's low and 3.3% below its high.

Volume so far is 6.66M shares, in line with the average of 6.81M shares a day.

Over the past year Ocugen has ranged from $0.7803 to $2.73, and now sits 2% of the way up that range.

Ocugen met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.0544.

The average analyst price target is $12.41, 1427.4% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $12.41
Low
$8.08
Now
$0.8125
High
$23.10

OCGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 11.1% on average.

  1. Q3 FY24: reported -$0.05 per share against an estimate of -$0.0544
  2. Q4 FY24: reported -$0.05 per share against an estimate of -$0.0536
  3. Q1 FY25: reported -$0.05 per share against an estimate of -$0.0587
  4. Q2 FY25: reported -$0.05 per share against an estimate of -$0.0587
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0571
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0592
  7. Q1 FY26: reported -$0.06 per share against an estimate of -$0.0525
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0544

OCGN news

  • Press releasePRNewswire

    Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Henry Khederian

    What's Happening With Ocugen Stock Thursday?

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releasePRNewswire

    Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

  • Vandana Singh

    Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

  • Press releasePRNewswire

    Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

  • Henry Khederian

    Ocugen Stock Is Surging Today: What's Driving The Action?

  • Forecasting The Future: 4 Analyst Projections For Ocugen

Similar companies

Companies in the same industry as Ocugen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.